Barts Cancer Institute book celebrates two decades of cancer discovery
Today on World Cancer Day, Barts Cancer Institute, Queen Mary Univerity of London, is delighted to announce the publication of a special commemorative book celebrating two decades of cancer discoveries since the establishment of the institute.
The volume, titled Knowledge is Power: Working Together to Outsmart Cancer, contains contributions from 18 eminent cancer researchers who reflect on the successes and challenges across two decades of deciphering cancer's complexities. The authors also look ahead to promising new horizons and the future of cancer research.
To celebrate this milestone and make this work accessible to all, we are making the digital version of the book available for free to download. Physical copies of the book are also available on request to friends of the institute – contact us for more details.
The book is dedicated to the staff and students of the institute, past, present and future, without whom none of the achievements in this volume would be possible.
Below, we share the first chapter of the book, written by Professor Kairbaan Hodivala-Dilke, Deputy Director and Centre Lead for the BCI's Centre for Tumour Microenvironment. She reflects on her memories of the early days of the institute, the people who helped to make it a success, and how it has evolved over the past 20 years.
Introduction: a brief history of the BCI
Professor Kairbaan Hodivala-Dilke
Happy 20th Birthday, Barts Cancer Institute. Here’s wishing you many, many more.
In 2004, Facebook was launched, NASA landed the Opportunity Rover on Mars, and the Barts Cancer Institute (BCI) was born. And now, here we are, celebrating the BCI’s 20th birthday. As I reflect on the past 20 years, the most overwhelming emotion is how much the BCI family has grown and grown, from strength to strength.
In 2003, I remember visiting the John Vane Science Centre at Charterhouse Square for the first time with some of the giants of the institute. Professor Sir Nick Wright – the Medical School Warden (now termed Vice-Principal for Heath) at that time – led the way, striding strong and laughing loudly. Professor Nick Lemoine – a hugely ambitious young clinician scientist with a spark in his eye – was excited and confident, knowing exactly how he would build and direct this institute to become a world-class cancer research beacon.
"As I reflect on the past 20 years, the most overwhelming emotion is how much the BCI family has grown and grown, from strength to strength."
Professor Ian Hart – the first BCI Deputy Director – was a truly kind-hearted scientist. He started as a veterinarian (‘too clever to become a doctor’, in his own words) and is someone I am so proud to call a mentor, teacher and friend. On that day, behind these giants, walked the young and keen Dr John Marshall, who actually brought his tape measure with him to work out bench lengths. And finally, there was me, just finishing my Imperial Cancer Research Fund (ICRF, now Cancer Research UK) tenure track position, pregnant with my first baby, and struggling to keep up the pace.
My first impression was: such a beautiful leafy square! Especially compared with the lonely, concrete Rayne Institute at St Thomas’s Hospital, where Ian, John and I started. At Charterhouse Square, we were greeted by smiling Jimmy, the gardener who cared for the grounds until his retirement in 2024. At that time, the John Vane Science Centre housed corridors of tiny office-like rooms on the ground floor, with hospital trolleys and beds randomly scattered about and no one, apparently, around. There were no working laboratories on the ground floor, but there was an out-of-place library for the Queen Mary Law department, where the Centre for Tumour Biology now has part of its laboratories. But mostly, what I remember is being so excited at the thought of being there at the beginning of what was clearly going to be an amazing journey to grow this new Barts Cancer Institute.
Sir Nick, Nick and Ian, the Three Musketeers, were together hooking in the biggest and the best talent to join us, and I can tell you that people were beating at the door to be let in. Right at the start, Dr Delphine Purves was appointed Institute Manager and instantly became the hub of the institute. A young woman in high-heeled shoes from the Wellcome Trust, Delphine’s drive and financial wizardry meant that when she cracked the whip, things happened. She is still the single person who holds the BCI together. She was appointed and mentored by the Chief Operating Officer, Peter Davies – the “Dumbledore” of financial wizardry who taught her almost everything she knows and was always willing to invest in the BCI to make Sir Nick’s vision a reality. Not long after, Kaye Yeung was onboard as Delphine’s Cagney to her Lacey. The team was set! Nothing was stopping us.
The establishment of the BCI also meant joining with major forces who were already running ICRF-supported laboratories embedded in the John Vane Science Centre. The Centre for Medical Oncology (which later transformed into the Centre for Haemato-Oncology) was run by the great Professor Andrew Lister, who had been at the ICRF Medical Oncology Unit since 1977. To this day, you’ll recognise him by being the only one in the building wearing a dapper bow tie, peering over half-moon glasses at you and setting the facts straight.
"Professor Andrew Lister... impressed us all by always putting the patients first and was famous for serving Christmas dinner in the wards before he and his family ate."
As Clinical Director of the Cancer Services at Barts, Professor Lister developed one of the largest units treating haematological malignancies in the country. He impressed us all by always putting the patients first and was famous for serving Christmas dinner in the wards before he and his family ate. He was truly adored by his patients and hugely respected by his colleagues. His right-hand team, Simon Joel (Professor of Pharmacology), Bryan Young (Professor of Medical Oncology) and the young Jude Fitzgibbon (later to become Professor of Personalised Cancer Medicine), welcomed us into the building.
"An inspiration to scientists, both men and women, Professor Balkwill was ahead of her time in reminding people that cancer is more than malignant cells."
Also in the John Vane Science Centre was Professor Fran Balkwill, who ran the Centre for Translational Oncology, which later turned into the Centre for Cancer and Inflammation and now the Centre for Tumour Microenvironment. Fran was the only woman to hold a Centre Lead position at the time. She is also a famous author of children’s books – with over 500,000 copies sold, bringing science to life in twelve languages. An inspiration to scientists, both men and women, Professor Balkwill was ahead of her time in reminding people that cancer is more than malignant cells!
At the very beginning, Nick, Ian and Delphine had an inspired idea that was not commonplace in other institutes. They decided to shape the BCI into centres, each with multiple laboratories and principal investigators (PIs). We take this for granted now, but I had only worked in places where each lab worked alone, like the old ICRF at Lincoln’s Inn Fields and the Massachusetts Institute of Technology, where I worked as a postdoc. Being a relatively new PI at the time, I can tell you that there is nothing more frightening than being given an empty room and told to get on with it! Organising the BCI into centres was an insightful move because everyone was instantly part of a team, working together and immediately productive. This was a colossal draw, attracting others to join us. The strengths and fun that came with being part of a team were second to none. Of course, the inter-centre ‘healthy’ competition did exist – more in the name of pride than anything else. All gloves were off when it came to the BCI summer sports day, with becoming the winning centre the only goal.
In those early years, we had six integrated Centres:
On the ground floor: the Centre for Tumour Biology led by Ian Hart. Not long after his arrival, Ian, together with John Marshall, began to build a rapidly growing snowball of new recruits. Louise Jones (a.k.a. ‘Jones the Breast’) came from Leicester and proved to have a boundless capacity. She not only is a truly world-leading breast pathologist and teacher but also leads the Breast Cancer Now National Biobank (that we all rely on) and is the most inspiring and compassionate laboratory head and collaborator. Richard Grose (a.k.a. ‘Uncle Dickie’) and Professor Stephanie Kermorgant – both cell signalling aficionados – joined us from ICRF Lincoln’s Inn Fields, after completing their postdoctoral fellowships with the hugely respected Clive Dickson and Peter Parker labs. Hemant Kocher – a hepatobiliary surgeon with a lust for academic research – was famous for his brightly coloured schematics and his deep commitment to two things: cricket and making a difference in pancreatic cancer research (which he certainly has, through his work on all-trans-retinoic acid (ATRA) as a novel therapy).
Spread across the ground floor and basement was the Centre for Molecular Oncology, led by our inaugural Director, Nick Lemoine. He brought with him a core team from Imperial College London and Hammersmith Hospital: Yaohe Wang, Gunnel Hallden and Tatjana Crnogorac-Jurcevic. Yaohe – another pathologist and young lecturer – always seems to be smiling and never seems to age. His eagerness allowed him to create an incredible impact on viral therapy that has now exploded into a spin-off company, VacV, led by him and Nick. Gentle and modest Gunnel is now Director of Oncolytic Virotherapy and Antibody-drug conjugate (ADC) Biology at AstraZeneca. Meanwhile, Tatjana’s interest in the molecular pathology of pancreatic cancer has led to a patented novel non-invasive diagnostics test for the early detection of pancreatic cancer. Soon after, they were joined by Yong-Jie Lu – a perpetually eager scientist with a passion for predicting prostate cancer onset – and another of Nick’s recruits, Iain McNeish – a tall and kind medical oncologist with a focus on translational research and therapy development in ovarian cancer, who used to walk around the lab in his cycling lycra, whistling. He later took over leading the Centre. Michelle Lockley arrived as Iain’s clinical research fellow and eventually joined as a young Clinical Senior Lecturer, employing her poise and drive to improve treatment for women with ovarian cancer. Soon after, Claude Chelala and Jun Wang (a.k.a Alex) arrived to lead our bioinformatics initiatives. Bringing numbers to our observations was a new idea at the time, and the bioinformatics service would ultimately transform research across the BCI, thanks in large part to Claude and Alex’s active and collaborative natures.
On the third floor, the Centre for Haemato-Oncology was taken over by Professor John Gribben, an eminent haemato-oncologist who had flown all the way from Harvard to be with us. Stepping into Andrew Lister’s shoes, John was in exactly the right place. It wasn’t long before the Centre began to expand, becoming the home of the vast majority of BCI’s clinical colleagues, including Ama Rohatiner, Vaskar Saha, Louise Jones, Heather Oakervee, Silvia Monoto, Rebecca Auer, Finbar Cotter, Li Jia, Jeff Davies and David Taussig, all underscoring our essential links with patients. Not long after John’s arrival, Jessica Okosun was also recruited under Jude’s umbrella as a Clinical Research Fellow. A highly talented and intelligent young scientist thirsty for discovery research, Jessica exudes a calmness that infiltrates those around her like a hot milky drink before bedtime. After her fellowship, she came back as a Clinical Senior Lecturer in 2017 and today has become Deputy Centre Lead of HaemOnc.
The Centre for Cancer and Inflammation, led by Fran Balkwill, was also home to the young Peter Szlosarek, who exemplifies bench-to-bedside achievements in melanoma and mesothelioma research. Peter started as a Clinical Research Fellow in Fran’s lab in 1997, started his postdoc with her in 2005, and then left and came back in 2008 as a Clinical Lecturer. Over several decades, Peter has translated his early lab observations into an arginine-depleting agent, ADI-PEG20, which is creating an impact in several hard-to-treat cancers (and I should say, he is also one of the best dancers at BCI parties).
"Over several decades, Peter [Szlosarek] has translated his early lab observations into an arginine-depleting agent, ADI-PEG20, which is creating an impact in several hard-to-treat cancers."
Toby Lawrence also joined us as a Senior Lecturer and has become a leading expert in macrophage biology, now based at King’s College London. David Propper is our resident clinical expert, who provides insight and direction to our research from the perspective of his patients. The centre, today known as the Centre for Tumour Microenvironment, is now home to some of Fran’s home-grown new group leaders, including Oliver Pearce – a chemist by training who brings elegance to our understanding of the extracellular matrix – and most recently, Samar Elorbany – a young clinical surgical lecturer with a passion and drive to beat drug resistance in ovarian cancer for good.
Not long after the initial set-up of the BCI, the Centre for Cell Signalling was formed. This was led by Bart Vanhaesebroeck, who had made discoveries in PI3K signalling that we were all envious of. Bart brought with him Pedro Cutillas, a young and brilliant scientist with the inventiveness and foresight to invest in one of the first ‘omics’ platforms of the time – phosphoproteomics. Today, Pedro runs a successful spinout company, Kinomica, and he remains our go-to BCI proteomics expert: patient, knowledgeable and always happy to collaborate.
In the basement, Stephen Mather and Jane Sosabowski moved from the Nuclear Medicine Department at St Bartholomew’s Hospital, bringing their world-class in vivo imaging to strengthen the BCI’s foundations even further. This gave the BCI one of its most important and unique selling points. Almost nowhere else in the UK was conducting in vivo imaging at this level, and it was exciting to watch this group grow from strength to strength over the years, even after Steve’s retirement.
The BCI also recruited a couple of extremely talented young scientists, Melania Capasso and Sarah Anne Martin, working on B cells and DNA, respectively. Sarah also went on to become our Director of Graduate Studies. Always compassionate, calm and supportive to all our PhD students, she was a linchpin of our community. Nick and Ian set the expectation bar ridiculously high for Melania and Sarah’s probation, and they both rose to the challenge without flinching. I am so proud of them both. It was just the first of many exciting opportunities to see young scientists really flourish, thanks to being nurtured at BCI.
By 2008, in less than five years of existence, the BCI was ranked third in the country for cancer research in the UK’s Research Assessment Exercise (now the Research Excellence Framework) – you can’t argue with that.
In 2014, Ian wrote beautifully about the first ten years of the Barts Cancer Institute in the first volume of this series, where he waxed lyrical about the transition from the Imperial Cancer Research Fund to Cancer Research UK (CRUK) and more, so I’ll let you read all about that in his words. But what about since then?
When Professor Hart retired (and after much partying, weeping and a little drinking), Iain McNeish took the reins as Deputy Director. Tyson Sharp arrived – a young scientist from York, bringing his expertise in LIMD1, a gene that causes lung cancer. Tyson soon became the lead of the renamed Molecular Oncology Centre (now our Centre for Cell and Molecular Biology). Meanwhile, Sir Nick graciously took the lead for the Centre for Tumour Biology. I remember that at the first Tumour Biology centre meeting, Sir Nick said that he considered being our Centre Lead a promotion from being the Medical School Warden! He always started each centre meeting with, ‘So, what’s the good news?’ – a true gentleman.
Sir Nick soon brought with him a team that would turn out to be one of the strongest assets to BCI. Trevor Graham came to us from the USA – a very young and seemingly quiet mathematician, Trevor introduced us to cancer evolution and has been a rising star since then, leaving us in 2022 to become the Director of the Centre for Evolution and Cancer at the Institute of Cancer Research. Stuart McDonald also joined us, bringing his special expertise to the causes of oesophageal cancer that we were sorely lacking at BCI.
Getting these world-class scientists to all work together was so exciting, and it seemed that the BCI was unstoppable. But there’s no success without funding. In those early years, CRUK changed its style of support and many of us moved from CRUK to Queen Mary University of London employment contracts. This was all part of CRUK’s great plan to start to spread funding across what they called Centres of Excellence to support the training and technical facilities of their best researchers. So, in 2009, the BCI combined forces with the CRUK-supported Centre for Cancer Prevention in Queen Mary’s Wolfson Institute of Preventive Medicine (now the Wolfson Institute of Population Health) to become London's first CRUK Centre of Excellence. With only a handful of such Centres scattered across the country, we were certainly shoulder-to-shoulder with the elite class of cancer researchers in the UK.
The Wolfson was led by Professor Jack Cuzick, a Californian-born mathematician whose focus shifted into epidemiology. Jack sat firmly at the international forefront of preventative cancer research, transforming the identification of women at high risk of breast cancer and pioneering modern prevention breast and cervical screening strategies that have been adopted worldwide. Together with his colleagues, Professor Stephen Duffy (a true Scottish gentleman and statistician) and Professor Peter Sasieni (tall in stature and scientific ambition), Jack brought early detection of cancer research to a globally recognised level.
"Getting these world-class scientists to all work together was so exciting, and it seemed that the BCI was unstoppable."
The CRUK-funded Barts Centre, as it was then known, was renewed in 2014 for a further five years, with extra funds offered. I don’t think I have ever heard of CRUK giving more money than was applied for, but I think it was a true recognition of our strengths and their faith in us and cancer research.
With the CRUK Barts Centre looking to invest in the future, our first cohort of Early-Career researchers joined us around that time: Katiuscia Bianchi, Gabriella Ficz, Susana Godinho, Trevor Graham, Sarah McClelland, Paulo Ribeiro and Angus Cameron (who recently has become our new Director of Graduate Studies, following Sarah Anne Martin's departure to head up student programmes at the Crick). Soon after, we were also joined by Andrejs Braun (now our Director of Education), Bela Wrench, Prabhakar (Prabs) Rajan, Kevin Rouault-Pierre, Sergey Krysov, John Riches, Zuzana Horejsi and Faraz Mardakheh. Spread across the BCI, these eager scientists were keen and hungry to succeed at a level we couldn’t have imagined. They work across the institute in a diverse array of disciplines, including signalling, epigenetics, chromosome biology, Drosophila modelling and metabolism. We are all so proud of how they have all exceeded the high bars of performance set before them.
As the years went on, CRUK’s stance on funding began to change once again, and whispers of merging CRUK Centres of Excellence to become CRUK Major Centres became a reality. In 2018, we joined forces with University College London (UCL), King’s College London, and the then gleaming and new Francis Crick Institute to become part of the CRUK City of London Major Centre.
Long meetings over several months shaped this new idea and brought together the kings of cancer research from each of these organisations. Together, they would amalgamate into a super-force: Professor Tariq Enver, a stem cell biologist by trade who leads the Cancer Centre at UCL; Professor Peter Parker, a PKC signalling expert from King’s and the Crick; Sir Richard Treisman, Director of Research at the Crick who discovered serum response factor (a central factor in MAPK signalling), and our own Nick Lemoine. The idea that a cross-organisational Major Centre would ever materialise was totally alien to me, but Nick knew that he could make it work. It’s another example showing that if I say ‘it won’t fly’, Nick will prove me wrong and make it a massive success.
"The idea that a cross-organisational Major Centre would ever materialise was totally alien to me, but Nick knew that he could make it work. It’s another example showing that if I say ‘it won’t fly’, Nick will prove me wrong and make it a massive success."
The City of London Major Centre in Biotherapeutics had three cross-organisational themes: developing biological therapies, cross-disciplinary approaches in enhancing biotherapeutics and cancer evolution and tumour heterogeneity. The City of London Centre was renewed in 2022, at which point the individual CRUK Centres of Excellence at Queen Mary, King's and UCL were merged. It continues to support many of our essential facilities and clinical and non-clinical PhD students. It is the absolute exemplar of cross-organisational work, cleverly blending collaborative work through cross-organisational joint supervision of projects and PhD students. This approach has seeded joint projects that would have otherwise never happened. It is this teamwork that puts our CRUK City of London Centre firmly at the epicentre of international cancer research. We must remember that cross-organisational work is rarely found and provides immense strength to the work at all partner institutes. Around this time, Trevor and Jude also set up the BCI’s new Centre for Genomic and Computational Biology, which enabled us to shuffle people to work together on cancer evolution and mathematics, setting us up with a flag of international recognition in the field.
"Tom Powles and Peter Schmid ... have worked tirelessly, spending much of their lives on planes, to cement international industrial sponsorship and accelerate the clinical successes of immunotherapy."
BCI’s contribution to the City of London Centre also relied heavily on the internationally recognised successes of our Barts Health Cancer Centre leads, Tom Powles and Peter Schmid, who have worked tirelessly, spending much of their lives on planes, to cement international industrial sponsorship and accelerate the clinical successes of immunotherapy in urogenital and breast cancers and who have taken our outputs to the heady heights of publications in Nature, Nature Medicine and New England Journal of Medicine – truly inspirational members of the family.
We have also worked with our colleagues in Queen Mary’s Faculty of Medicine and Dentistry (FMD) on some ground-breaking projects. In 2013, Professor Sir Mark Caulfield – at that time the Director of the William Harvey Institute and today our Vice-Principal for Health – was appointed Chief Scientist for Genomics England and charged with delivery of the 100,000 Genomes Project on whole genome sequencing. It was our Professor Louise Jones who linked BCI into this amazing venture, taking on the role of Lead for Molecular Pathology for Genomics England amongst everything else that she does. More recently, Louise Jones and Tom Powels, together with our colleagues from the William Harvey Institute, were instrumental in ensuring the establishment of the first National Institute for Health and Care Research (NIHR) Barts Biomedical Research Centre and became co-leads of the Precision Cancer Care Research Theme taking the FMD’s science from strength to strength.
In 2020, the COVID pandemic closed down the building for a while, but not the research – Delphine and the fantastic lab support teams, including Vipul Bhakta and Bex Gresham, made sure of that. The renewed CRUK City of London Centre attracted a second cohort of early-career scientists to the BCI: Roberto Bellelli, Lovorka Stojic and Tanya Soliman – all hardcore molecular biologists; Mirjana Efremova – single-cell transcriptomics wizard; Miguel Ganuza Fernandez – haematopoietic stem cell expert; Luigi Ombrato – metastasis and tumour microenvironment specialist; Barrie Peck and Andy Finch – both enriching the cancer metabolism energy even further; and Bennie Werner – cancer mathematician with an incredible ability to explain cancer evolution using numbers. And as if that was not enough, BCI attracted the talent of Vicky Sanz-Moreno, formally at King’s College London – an amazing tornado of expertise in the cancer metastasis tumour microenvironment; and Kamil Kranc from Edinburgh – a super-driven stem cell and hypoxia expert. John Marshall and Richard Grose took over leading the Centre for Tumour Biology, and I had the honour of working more closely with Fran in leading the Centre for Tumour Microenvironment.
Since 2022, our most recent newcomers have enriched the BCI even further with Diu Nguyen – with her expertise in leukaemia; Ozgen Deniz – with her expertise in epigenetics; Marco Gerlinger – from ICR, working on cancer cell heterogeneity; and Paolo Gallipoli – a clinical reader in experimental haematology. All of these new starters have also brought in fellowships and funding at an amazing level. In 2023, we welcomed Francesca Ciccarelli, who came to us from the Crick and King’s College London to head up the Genomics and Computational Biology Centre at BCI – a vibrant mathematician with a fervour for understanding cancer evolution. This year, we welcome the young Vivek Singh and Oscar Maiques Carlos – both bringing digital pathology with AI to BCI.
I can’t close without dedicating the end of this chapter to honouring Nick Lemoine, CBE, MD, PhD, FRCPath, FMedSci. Nick has truly been the beating heart of BCI, driving it from the 75 staff that we started with in 2003 to over 420 in 2024. I am so proud to have had the opportunity to serve as his Deputy. I remember seeing him through the Boardroom window, working late into the night and at the weekends without tiring. It is his work and constant dedication to BCI (literally blood, sweat and tears) that has made us one of the top-ranking cancer institutes nationally and internationally. His legacy is immense, and I can highlight only a few of his accomplishments here.
Over the years, Nick has not only run his own laboratory and centre but nurtured all our careers and personally mentored over 150 discovery and clinical postdocs and students. He has published over 280 papers and personally held no less than three CRUK programme grants simultaneously in the earliest years of the BCI. He knows all of us and our science. He has always remained calm and collected, an iron rod of stability, and an advocate for transparency and honesty. And all of this without ever boasting about his own successes.
"I remember seeing [Nick] through the Boardroom window, working late into the night and at the weekends without tiring. It is his work and constant dedication to BCI (literally blood, sweat and tears) that has made us one of the top-ranking cancer institutes nationally and internationally. "
Nick has also provided important service to the FMD, representing BCI at Queen Mary Council and Senate. He was the original Chair of the Athena Swan committee, which successfully brought the first Athena Swan Bronze accreditation to FMD. He has been the FMD representative for Barts Health NHS Trust, where he was also the Director of Cancer Services. Since 2013, he has been the Medical Director of the NIHR. He has served and chaired countless national and international funding committees, including at the MRC Foundation and CRUK. In 2017, Nick was elected Foreign Academician of the Chinese Academy of Engineering – one of only 18 people worldwide – in recognition of his work on engineering new therapies for cancer in the Sino-British Center for Molecular Oncology (established as a joint venture between Queen Mary and Zhengzhou University in 2006) and his creation of the Academy of Medical Sciences in China.
He was appointed Commander of the Order of the British Empire (CBE) in the 2022 New Year Honours for services to clinical research, for taking a leading role in orchestrating the NIHR’s coordinated response to the COVID-19 pandemic. This included chairing the Urgent Public Health group, which identified and ensured the delivery of the 100 most vital COVID-19 studies and leading the Long COVID awards scheme, which has seen more than £50m invested into 19 studies on this disease. I know I speak for us all when we thank him for being a devoted mentor and unwavering leader. If you’ve worked with Nick, he will have changed your life. After 20 years of leadership as Director of the BCI, Nick is stepping down to continue his work in the Centre for Cancer Biomarkers and Biotherapeutics lead. We wish his successor, Nitzan Rosenfeld, the very best as he takes on the role of Director of BCI.
"There’s no ‘impact factor’ for working together, but if there were, we would score higher than any other institute that I know."
So, in 20 years, we’ve grown from 75 to 421 staff at BCI. We’ve raised cumulative funds in excess of £100m in just the past five years. The BCI is a place where people really work together, and we now cover all angles of cancer biology, signalling and molecular regulation, bioinformatics, stem cell biology, evolution, metabolism, biotherapies, tumour microenvironment, multi-omics analysis, spinout companies rising and much more.
I think sometimes we take the BCI community and working together for granted. But it’s true: it is the core of our success and hard to find elsewhere. I apologise here if I have excluded any details of your contribution since space was limited, but rest assured that your contribution to the team is valued. There’s no ‘impact factor’ for working together, but if there were, we would score higher than any other institute that I know. Even those who have flown the nest along the way will say that there is something special about the Barts Cancer Institute that they can’t substitute for anywhere else.
Happy 20th birthday BCI. Here’s looking forward to even more success over the many, many years to come.
Category: General News, Publications
No comments yet